CN104877961A - Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof - Google Patents
Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof Download PDFInfo
- Publication number
- CN104877961A CN104877961A CN201510176971.6A CN201510176971A CN104877961A CN 104877961 A CN104877961 A CN 104877961A CN 201510176971 A CN201510176971 A CN 201510176971A CN 104877961 A CN104877961 A CN 104877961A
- Authority
- CN
- China
- Prior art keywords
- human
- growth factor
- stem cell
- serum
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a serum-free human amniotic mesenchymal stem cell culture medium, which belongs to the technical field of stem cells, and comprises an IMDM (intrinsic mode division multiplexing) basic culture medium and the following components: recombinant human insulin, recombinant transferrin, vitamin C, human serum albumin, fibroblast growth factor, platelet derived growth factor, epidermal growth factor, insulin-like growth factor, transforming growth factor, fibronectin, fetuin, putrescine salt and recombinant human activin. The serum-free human amniotic mesenchymal stem cell culture medium provided by the invention does not need culture flask coating, and has good cell adherence and morphology and high cell proliferation rate.
Description
Technical field
The invention belongs to stem cells technology field, human amnion mesenchymal stem cell substratum relating to a kind of serum-free and preparation method thereof.
Background technology
Human amnion mesenchymal stem cell is derived from placenta amnion tissue, it is a kind of adult stem cell with obvious plasticity-and multi-lineage potential, under the adjustment of different somatomedin, the different tissues cell type deriving from 3 germinal layers can be divided into, as adipocyte, scleroblast, hepatic lineage, cardiac-like muscle cell, neurogliocyte, neuronal cell and insulin-like cell etc.Except this, human amnion mesenchymal stem cell does not express ajor histocompatibility II class antigen, trace expression ajor histocompatibility I class antigen, immunogenicity is low, transplant rejection effect is little, and there is immunomodulatory effect, the nutritional factor of the human amnion mesenchymal stem cell secretion after transplanting, has the effects such as Angiogensis, promoting growth of cell, anti-inflammatory and anti-fibrosis.
Traditional stem cell media containing animal serum brings multiple unfavorable factor to the production and scientific research of stem cell.Serum can provide hormone, somatomedin, transfer protein and other nutritive substance needed for growing multiplication for stem cell, but there is shortcomings in it: differences between batches are larger, source is unstable, need to verify work in a large number, expensive, use inconvenience, composition is indefinite, there is cytostatic composition, be unfavorable for the object such as vaccine and monoclonal antibody product separation purifying, easily by virus and mycoplasma infection etc.Serum free medium is on the basis of basic medium, adds the blood serum substituting composition of definite ingredients, can meet the fostering requirement of stem cell, effectively can avoid again the many unfavorable factors because using serum to bring.Therefore, developing serum free medium is the essential condition that stem cell moves towards clinical application.
More existing commercially available mesenchymal stem cell serum-free culture mediums at present, the mesenchymal stem cell serum-free culture medium StemPro SFM of such as Life Technology.But there is the defect such as cell attachment difference, operation inconvenience in existing commercially available serum free medium.The such as application of Gibco serum free medium, Stem CELL serum free medium needs to carry out culturing bottle bag quilt.In addition, the cell proliferation rate of these culture medium culturing is not ideal enough.
Chinese patent CN 101914490 discloses a kind of human amnion mesenchymal stem cell serum-free culture medium, this substratum substratum based on DMEM/F12, with the addition of human serum albumin, human transferrin, insulin human and Sodium Selenite, achieve the cultivation of human amnion mesenchymal stem cell, but this substratum lacks anchoring factor, cell attachment can be caused poor, and therefore cell cannot breed.
Chinese patent CN 102433302 discloses a kind of serum free medium, this substratum substratum based on DMEM/F12, but this invention substratum only has a kind of anchoring factor, and cell attachment performance is not ideal enough.
The problems such as therefore, it is poor that prior art exists cell attachment, and cell proliferation rate is not ideal enough.
Summary of the invention
Poor for solving the cell attachment existed in prior art, the problems such as cell proliferation rate is not ideal enough, contriver is screened by lot of experiments, obtain a kind of human amnion mesenchymal stem cell substratum of new serum-free, this substratum is without the need to carrying out culturing bottle bag quilt, easy and simple to handle, well, cell proliferation rate is high for cell attachment and form.
Object of the present invention will be further described in detail below reflect and description.
The invention provides a kind of human amnion mesenchymal stem cell substratum of serum-free, comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 0.5 ~ 5mg/mL, recombinant transferrin 1 ~ 5 μ g/mL, vitamins C 5 ~ 50 μ g/mL, human serum albumin 0.5 ~ 5mg/mL, FGF5 ~ 50ng/mL, Thr6 PDGF BB 5 ~ 50ng/mL, Urogastron 5 ~ 50ng/mL, rhIGF-1 5 ~ 50ng/mL, transforming growth factor 5 ~ 50ng/mL, fibronectin 5 ~ 50ng/mL, Pp63 glycophosphoproteins 0.5 ~ 5mg/mL, putrescine salt 2 ~ 20 μ g/mL and recombinant human activator 2 ~ 20ng/mL.
Adopt the human amnion mesenchymal stem cell substratum of the serum-free of technique scheme, without the need to adding animal serum, the fast breeding of human amnion mesenchymal stem cell can be realized, maintaining good stem cell puerilism, there is good cell induction differentiation potential.
In the human amnion mesenchymal stem cell substratum of serum-free provided by the invention, by the synergy of Fibronectin (fibronectin) and Pp63 glycophosphoproteins (Fetuin), greatly strengthen the adherent performance of human amnion mesenchymal stem cell; Putrescine hydrochloride contributes to the puerilism maintaining stem cell, prevents the aging of stem cell; Recombinant human activator then can promote the propagation of amnion mesenchymal stem cell.
Preferably, the human amnion mesenchymal stem cell substratum of serum-free provided by the invention, comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 0.5 ~ 2mg/mL, recombinant transferrin 1 ~ 4 μ g/mL, vitamins C 5 ~ 30 μ g/mL, human serum albumin 0.5 ~ 2mg/mL, FGF5 ~ 20ng/mL, Thr6 PDGF BB 5 ~ 20ng/mL, Urogastron 5 ~ 20ng/mL, rhIGF-1 5 ~ 20ng/mL, transforming growth factor 5 ~ 20ng/mL, fibronectin 5 ~ 20ng/mL, Pp63 glycophosphoproteins 0.5 ~ 3mg/mL, putrescine salt 5 ~ 15 μ g/mL and recombinant human activator 5 ~ 15ng/mL.
More preferably, the human amnion mesenchymal stem cell substratum of serum-free provided by the invention, comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 1mg/mL, recombinant transferrin 2.5 μ g/mL, vitamins C 16.1 μ g/mL, human serum albumin 1mg/mL, Fibroblast growth factor-10 ng/mL, Thr6 PDGF BB 10ng/mL, Urogastron 10ng/mL, type-1 insulin like growth factor 0ng/mL, TGF-1 0ng/mL, fibronectin 1 0ng/mL, Pp63 glycophosphoproteins 1mg/mL, putrescine salt 10 μ g/mL and recombinant human activator 10ng/mL.
Preferably, described fibroblast growth factor is Prostatropin, described Thr6 PDGF BB is PDGF-bb, described rhIGF-1 is insulin-like growth factor-i, described transforming growth factor is transforming growth factor-beta, described putrescine salt is putrescine hydrochloride, and described recombinant human activator is recombinant human activin A.
Preferably, the human amnion mesenchymal stem cell substratum of serum-free provided by the invention, also comprises the non-essential amino acid of 1% volume percent, such as, purchased from the nonessential amino acid of Sai Ye bio tech ltd, Guangzhou, and article No. NEAA-10201-100.
Correspondingly, the present invention also provides the preparation method of the human amnion mesenchymal stem cell substratum of serum-free, comprise the steps: in IMDM basic medium, recombinant human insulin's mother liquor is added by described concentration, recombinant transferrin mother liquor, vitamins C mother liquor, human serum albumin, fibroblast growth factor mother liquor, Thr6 PDGF BB mother liquor, Urogastron mother liquor, rhIGF-1 mother liquor, transforming growth factor mother liquor, fibronectin mother liquor, Pp63 glycophosphoproteins mother liquor, putrescine salt mother liquor and recombinant human activator mother liquor, stir, cross film degerming and get final product.
Preferably, described fibroblast growth factor is Prostatropin, described Thr6 PDGF BB is PDGF-bb, described rhIGF-1 is insulin-like growth factor-i, described transforming growth factor is transforming growth factor-beta, described putrescine salt is putrescine hydrochloride, and described recombinant human activator is recombinant human activin A.
Correspondingly, the present invention also provides the purposes of the human amnion mesenchymal stem cell substratum of serum-free in human amnion mesenchymal stem cell is cultivated.
Compared with prior art, the invention has the beneficial effects as follows: the human amnion mesenchymal stem cell substratum that the invention provides a kind of new serum-free, compare with other serum free mediums containing blood serum medium with traditional, the human amnion mesenchymal stem cell of culture medium culturing provided by the invention can keep good stem cell pedomorphism, has better cell proliferation rate, cell dryness and cell induction differentiation potential.Preparation method provided by the invention is simple, and the human amnion mesenchymal stem cell substratum of obtained serum-free is used for the cultivation of human amnion mesenchymal stem cell, shows excellent cell performance.
Accompanying drawing explanation
The impact of the human amnion mesenchymal stem cell substratum on cell proliferation of Fig. 1 different ingredients.
The form that Fig. 2 P5 cultivates in 3 kinds of substratum for human amnion mesenchymal stem cell.
The growth curve of Fig. 3 human amnion mesenchymal stem cell in 3 kinds of substratum.
Fig. 4 P3 is for the cell clone quantity of human amnion mesenchymal stem cell in 3 kinds of substratum.
The P5 that Fig. 5 substratum 1 is cultivated is for the surface antigen expression level of human amnion mesenchymal stem cell.
The P5 that Fig. 6 substratum 2 is cultivated is for the surface antigen expression level of human amnion mesenchymal stem cell.
The P5 that Fig. 7 substratum 3 is cultivated is for the surface antigen expression level of human amnion mesenchymal stem cell.
The P5 of Fig. 83 kinds of culture medium culturing is for the adipogenic induction differential stain result figure of human amnion mesenchymal stem cell.
The P5 of Fig. 93 kinds of culture medium culturing is for the expression of results figure of the adipogenic induction differentiation associated gene FABP4 of human amnion mesenchymal stem cell in inducing culture.
The P5 of Figure 10 3 kinds of culture medium culturing is for the Osteoinductive differentiation coloration result figure of human amnion mesenchymal stem cell.
The P5 of Figure 11 3 kinds of culture medium culturing is for the expression of results figure of the Osteoinductive differentiation genes involved OPN of human amnion mesenchymal stem cell in inducing culture.
Embodiment
Below in conjunction with drawings and Examples, the present invention is described in further details.
Each component in the present invention is conventional commercial product.In the present invention, substratum 1: the human amnion mesenchymal stem cell substratum of the serum-free that the embodiment of the present invention two provides; Substratum 2:Life Tecnology company StemPro MSC SFM serum free medium, article No. A10332-01; The FBS of substratum 3:IMDM basic medium+10% volume percent; Substratum 4: compared with substratum 1, do not comprise putrescine hydrochloride.Substratum 5: compared with substratum 1, does not comprise recombinant human activin A.
the impact of the human amnion mesenchymal stem cell substratum on cell proliferation of embodiment one different ingredients
The human amnion mesenchymal stem cell substratum of contriver to serum-free has carried out lot of experiments screening.By P1 for HAMSC with 5000/cm
2density be inoculated in six orifice plates, add substratum 1, substratum 4 and substratum 5 respectively and cultivate, cell was used 0.25% trysinization in every 3 days, collecting cell number of computations, and with 5000/cm
2density inoculation culture again, until P5 generation, according to the cell harvesting quantity of each generation, draw cell proliferation curve, result is as shown in Figure 1.
As can be seen from Figure 1, add certain density putrescine hydrochloride and recombinant human activin A simultaneously, significantly can improve cell proliferation rate, and cellular form is more excellent.
the human amnion mesenchymal stem cell substratum of embodiment two serum-free
The human amnion mesenchymal stem cell substratum of serum-free, comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 1mg/mL, recombinant transferrin 2.5 μ g/mL, vitamins C 16.1 μ g/mL, human serum albumin 1mg/mL, bFGF 10ng/mL, PDGF-bb 10ng/mL, EGF 10ng/mL, IGF-1 10ng/mL, TGF-β 10ng/mL, fibronectin 1 0ng/mL, Pp63 glycophosphoproteins 1mg/mL, putrescine hydrochloride 10 μ g/mL and recombinant human activin A 10ng/mL.
Preparation method: in IMDM basic medium, recombinant human insulin's mother liquor, recombinant transferrin mother liquor, vitamins C mother liquor, human serum albumin, bFGF mother liquor, PDGF-bb mother liquor, EGF mother liquor, IGF-1 mother liquor, TGF-β mother liquor, fibronectin mother liquor, Pp63 glycophosphoproteins mother liquor, putrescine hydrochloride mother liquor and recombinant human activin A mother liquor is added by described concentration, stir, mistake film is degerming and get final product.
The preparation of recombinant human insulin's mother liquor: get 1g, uses 0.01mol/L dissolving with hydrochloric acid, is made into the mother liquor of 100mg/mL, and-20 degree are preserved.The preparation of recombinant transferrin mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 2.5mg/mL, and-20 degree are preserved.The preparation of vitamins C mother liquor: get 10g, dissolves with IMDM basic medium, is made into the mother liquor of 16.1mg/mL, and-20 degree are preserved.The preparation of bFGF mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 1mg/mL, and-20 degree are preserved.The preparation of PDGF-bb mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 1mg/mL, and-20 degree are preserved.The preparation of EGF mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 1mg/mL, and-20 degree are preserved.The preparation of IGF-1 mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 1mg/mL, and-20 degree are preserved.The preparation of TGF-β mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 1mg/mL, and-20 degree are preserved.The preparation of fibronectin mother liquor: get 10mg, dissolves with IMDM basic medium, is made into the mother liquor of 1mg/mL, and-20 degree are preserved.The preparation of Fetuin mother liquor: get 1g, dissolves with IMDM basic medium, is made into the mother liquor of 100mg/mL, and-20 degree are preserved.Putrescine hydrochloride: get 100mg, dissolves with IMDM basic medium, is made into the mother liquor of 10mg/ml, and-20 degree are preserved.Recombinant human activin A: get 100mg, dissolves with IMDM basic medium, is made into the mother liquor of 10mg/ml, and-20 degree are preserved.
the human amnion mesenchymal stem cell substratum of embodiment three serum-free
The human amnion mesenchymal stem cell substratum of serum-free, comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 1mg/mL, recombinant transferrin 2 μ g/mL, vitamins C 20 μ g/mL, human serum albumin 1mg/mL, bFGF 15ng/mL, PDGF-bb 10ng/mL, EGF 10ng/mL, IGF-1 10ng/mL, TGF-β 10ng/mL, fibronectin 1 5ng/mL, Pp63 glycophosphoproteins 3mg/mL, putrescine hydrochloride 15 μ g/mL and recombinant human activin A 10ng/mL.
Preparation method: similar with the preparation method in embodiment two.
the human amnion mesenchymal stem cell substratum of embodiment four serum-free
The human amnion mesenchymal stem cell substratum of serum-free, comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 2mg/mL, recombinant transferrin 1 μ g/mL, vitamins C 10 μ g/mL, human serum albumin 2mg/mL, bFGF 10ng/mL, PDGF-bb 15ng/mL, EGF 15ng/mL, IGF-1 10ng/mL, TGF-β 10ng/mL, fibronectin 1 0ng/mL, Pp63 glycophosphoproteins 2mg/mL, putrescine hydrochloride 10 μ g/mL and recombinant human activin A 15ng/mL.
Preparation method: similar with the preparation method in embodiment two.
the form that embodiment five human amnion mesenchymal stem cell is cultivated in the medium
By P1 for HAMSC with 5000/cm
2density be inoculated in culturing bottle, cultivate with substratum 1, substratum 2 and substratum 3 respectively, when cell confluency degree reaches 85%, carry out Secondary Culture, until P5 generation, basis of microscopic observation cellular form, result is as shown in Figure 2.As can be seen from Figure 2, substratum institute provided by the invention cultured cells form is more homogeneous, in fusiformis, maintain good stem cell puerilism, and the cellular form of other culture medium culturing differs, and presents ageing state.
the propagation that embodiment six human amnion mesenchymal stem cell is cultivated in the medium
By P1 for HAMSC with 5000/cm
2density be inoculated in six orifice plates, cultivate with substratum 1, substratum 2 and substratum 3 respectively, cell 0.25% trysinization got off in every 3 days, collecting cell number of computations, and with 5000/cm
2density inoculation culture again, until P5 generation, according to the cell harvesting quantity of each generation, draw cell proliferation curve, result is as shown in Figure 3.As can be seen from Figure 3, substratum provided by the invention 1 cultured cells multiplication rate is higher.
the clonal expansion that embodiment seven human amnion mesenchymal stem cell is cultivated in the medium
Getting P3 is inoculated in 10cm culture dish for HAMSC100, add 10mL substratum 1, substratum 2 and substratum 3 respectively to cultivate, within every 3 days, half amount changes liquid once, when contained by maximum cell clone, cell number is more than 200, dye by Viola crystallina, naked eyes calculate the cell clone quantity in culture dish, and result as shown in Figure 4.As can be seen from Figure 4, substratum provided by the invention 1 cultured cells clone is more.
the surface antigen that embodiment eight human amnion mesenchymal stem cell is cultivated in the medium is expressed
Use the P5 of substratum 1, substratum 2 and substratum 3 cultivation for cell in Example five respectively, the expression level of application flow cytometry cell-surface antigens CD59, CD45, CD90, HLA-DR, result as shown in Figures 5 to 7.From Fig. 5 to Fig. 7, substratum 1, substratum 2 and substratum 3 cultured cells surface antigen all meet the surface antigen requirement of human amnion mesenchymal stem cell.
the adipogenic induction differentiation potential that embodiment nine human amnion mesenchymal stem cell is cultivated in the medium
Use the P5 of substratum 1, substratum 2 and substratum 3 cultivation for cell in Example five respectively, with 5000/cm
2density be inoculated in six orifice plates, and add corresponding substratum 1, substratum 2 and substratum 3 and cultivate, when cell confluency degree reaches 80%, discard substratum, and add adipogenic induction division culture medium (purchased from Life Tecnology company, article No. A10070-01), within every 3 days, change liquid once, after cultivating 3 weeks, carry out into fat qualification with oil red O, result as shown in Figure 8.Meanwhile, identify the expression level of stearoblast genes involved FABP4 with qPCR, result as shown in Figure 9.From Fig. 8 and Fig. 9, substratum provided by the invention 1 cultured cells adipogenic induction differentiation potential is better.
the Osteoinductive differentiation potential that embodiment ten human amnion mesenchymal stem cell is cultivated in the medium
Use the P5 of substratum 1, substratum 2 and substratum 3 cultivation for cell in Example five respectively, with 5000/cm
2density be inoculated in six orifice plates, and add corresponding substratum 1, substratum 2 and substratum 3 and cultivate, when cell confluency degree reaches 80%, discard substratum, and add Osteoblast Differentiation substratum (purchased from Life Tecnology company, article No. A10072-01), within every 3 days, change liquid once, after cultivating 4 weeks, carry out skeletonization qualification by sodium alizarinsulfonate, result as shown in Figure 10.Meanwhile, identify the expression level of scleroblast genes involved OPN with qPCR, result as shown in figure 11.From Figure 10 and Figure 11, substratum provided by the invention 1 cultured cells Osteoinductive differentiation potential is better.
Above content is in conjunction with concrete preferred implementation further description made for the present invention, can not assert that specific embodiment of the invention is confined to these explanations.For general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, some simple deduction or replace can also be made, all should be considered as belonging to protection scope of the present invention.
Claims (8)
1. the human amnion mesenchymal stem cell substratum of a serum-free, it is characterized in that: comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 0.5 ~ 5mg/mL, recombinant transferrin 1 ~ 5 μ g/mL, vitamins C 5 ~ 50 μ g/mL, human serum albumin 0.5 ~ 5mg/mL, FGF5 ~ 50ng/mL, Thr6 PDGF BB 5 ~ 50ng/mL, Urogastron 5 ~ 50ng/mL, rhIGF-1 5 ~ 50ng/mL, transforming growth factor 5 ~ 50ng/mL, fibronectin 5 ~ 50ng/mL, Pp63 glycophosphoproteins 0.5 ~ 5mg/mL, putrescine salt 2 ~ 20 μ g/mL and recombinant human activator 2 ~ 20ng/mL.
2. the human amnion mesenchymal stem cell substratum of serum-free according to claim 1, it is characterized in that: comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 0.5 ~ 2mg/mL, recombinant transferrin 1 ~ 4 μ g/mL, vitamins C 5 ~ 30 μ g/mL, human serum albumin 0.5 ~ 2mg/mL, FGF5 ~ 20ng/mL, Thr6 PDGF BB 5 ~ 20ng/mL, Urogastron 5 ~ 20ng/mL, rhIGF-1 5 ~ 20ng/mL, transforming growth factor 5 ~ 20ng/mL, fibronectin 5 ~ 20ng/mL, Pp63 glycophosphoproteins 0.5 ~ 3mg/mL, putrescine salt 5 ~ 15 μ g/mL and recombinant human activator 5 ~ 15ng/mL.
3. the human amnion mesenchymal stem cell substratum of serum-free according to claim 2, it is characterized in that: comprise IMDM basic medium, also comprise following component and concentration thereof: recombinant human insulin 1mg/mL, recombinant transferrin 2.5 μ g/mL, vitamins C 16.1 μ g/mL, human serum albumin 1mg/mL, Fibroblast growth factor-10 ng/mL, Thr6 PDGF BB 10ng/mL, Urogastron 10ng/mL, type-1 insulin like growth factor 0ng/mL, TGF-1 0ng/mL, fibronectin 1 0ng/mL, Pp63 glycophosphoproteins 1mg/mL, putrescine salt 10 μ g/mL and recombinant human activator 10ng/mL.
4. the human amnion mesenchymal stem cell substratum of serum-free according to any one of claim 1 to 3, it is characterized in that: described fibroblast growth factor is Prostatropin, described Thr6 PDGF BB is PDGF-bb, described rhIGF-1 is insulin-like growth factor-i, described transforming growth factor is transforming growth factor-beta, described putrescine salt is putrescine hydrochloride, and described recombinant human activator is recombinant human activin A.
5. the human amnion mesenchymal stem cell substratum of serum-free according to any one of claim 1 to 3, is characterized in that: the non-essential amino acid also comprising 1% volume percent.
6. the preparation method of the human amnion mesenchymal stem cell substratum of serum-free according to claim 1, it is characterized in that: comprise the steps: in IMDM basic medium, recombinant human insulin's mother liquor is added by described concentration, recombinant transferrin mother liquor, vitamins C mother liquor, human serum albumin, fibroblast growth factor mother liquor, Thr6 PDGF BB mother liquor, Urogastron mother liquor, rhIGF-1 mother liquor, transforming growth factor mother liquor, fibronectin mother liquor, Pp63 glycophosphoproteins mother liquor, putrescine salt mother liquor and recombinant human activator mother liquor, stir, cross film degerming and get final product.
7. the preparation method of the human amnion mesenchymal stem cell substratum of serum-free according to claim 6, it is characterized in that: described fibroblast growth factor is Prostatropin, described Thr6 PDGF BB is PDGF-bb, described rhIGF-1 is insulin-like growth factor-i, described transforming growth factor is transforming growth factor-beta, described putrescine salt is putrescine hydrochloride, and described recombinant human activator is recombinant human activin A.
8. the purposes of human amnion mesenchymal stem cell substratum in human amnion mesenchymal stem cell is cultivated of serum-free according to any one of claim 1 to 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510176971.6A CN104877961A (en) | 2015-04-15 | 2015-04-15 | Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510176971.6A CN104877961A (en) | 2015-04-15 | 2015-04-15 | Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104877961A true CN104877961A (en) | 2015-09-02 |
Family
ID=53945641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510176971.6A Pending CN104877961A (en) | 2015-04-15 | 2015-04-15 | Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104877961A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107267444A (en) * | 2017-08-24 | 2017-10-20 | 广州润虹医药科技股份有限公司 | The method that culture medium and application thereof is converted with mescenchymal stem cell to sweat gland like cell |
| CN109022356A (en) * | 2018-08-30 | 2018-12-18 | 丰泽康生物医药（深圳）有限公司 | A kind of serum free medium improving mesenchymal stem cells into chondrocytes differentiation |
| CN109136178A (en) * | 2018-08-30 | 2019-01-04 | 丰泽康生物医药（深圳）有限公司 | A kind of raising serum free medium of the peripheral blood multipotential cell to Chondrocyte Differentiation |
| CN109136170A (en) * | 2018-08-20 | 2019-01-04 | 东北农业大学 | A kind of serum free medium and its application suitable for carp three times somatic growth |
| CN109652364A (en) * | 2018-12-29 | 2019-04-19 | 广州和能生物科技有限公司 | A kind of serum free medium of human amnion membrane |
| CN109943525A (en) * | 2019-03-15 | 2019-06-28 | 广州医科大学附属第三医院 | Serum-free, non-animal derived ingredient, the specific culture medium of component and its application |
| CN111040945A (en) * | 2019-12-30 | 2020-04-21 | 安徽惠恩生物科技股份有限公司 | Multi-type stem cell culture dish and culture medium thereof |
| CN111808807A (en) * | 2020-07-21 | 2020-10-23 | 生物岛实验室 | Mesenchymal stem cell serum-free medium without need of pre-coating and application thereof |
| CN112029717A (en) * | 2020-09-17 | 2020-12-04 | 英科博雅基因科技（天津）有限公司 | Serum-free in vitro domestication culture of human mesenchymal stem cells |
| CN113388574A (en) * | 2021-05-12 | 2021-09-14 | 生物岛实验室 | Serum-free and feed layer-free culture medium and culture method for effectively inhibiting stem cell differentiation |
| CN113512525A (en) * | 2020-04-10 | 2021-10-19 | 南京大学 | Mesenchymal stem cell preparation and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007108689A2 (en) * | 2006-03-21 | 2007-09-27 | Stichting Skeletal Tissue Engineering | Method for induction of differentiation of stem and progenitor cells |
| CN101412985A (en) * | 2007-10-15 | 2009-04-22 | 华东理工大学 | Serum-free medium for in vitro cultivation and amplification of mesenchymal stem cells |
| CN101984048A (en) * | 2010-11-24 | 2011-03-09 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Culture medium for culturing mesenchymal stem cells |
| CN102827807A (en) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | Serum-free culture medium for mesenchymal stem cells |
| CN103060264A (en) * | 2012-12-20 | 2013-04-24 | 上海市第十人民医院 | Stem cell culture medium and application thereof and stem cell cultivation method |
| CN103555665A (en) * | 2013-08-12 | 2014-02-05 | 北京东方华辉生物医药科技有限公司 | SFM (serum-free medium) for culturing MSCs (mesenchymal stem cells) |
| CN103857789A (en) * | 2011-08-31 | 2014-06-11 | 世元世龙技术株式会社 | Method for preparing a basic culture medium for mesenchymal stem cells, basic culture medium for mesenchymal stem cells, and cell therapeutic agent cultured and differentiated using same |
-
2015
- 2015-04-15 CN CN201510176971.6A patent/CN104877961A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007108689A2 (en) * | 2006-03-21 | 2007-09-27 | Stichting Skeletal Tissue Engineering | Method for induction of differentiation of stem and progenitor cells |
| CN101412985A (en) * | 2007-10-15 | 2009-04-22 | 华东理工大学 | Serum-free medium for in vitro cultivation and amplification of mesenchymal stem cells |
| CN101984048A (en) * | 2010-11-24 | 2011-03-09 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Culture medium for culturing mesenchymal stem cells |
| CN103857789A (en) * | 2011-08-31 | 2014-06-11 | 世元世龙技术株式会社 | Method for preparing a basic culture medium for mesenchymal stem cells, basic culture medium for mesenchymal stem cells, and cell therapeutic agent cultured and differentiated using same |
| CN102827807A (en) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | Serum-free culture medium for mesenchymal stem cells |
| CN103060264A (en) * | 2012-12-20 | 2013-04-24 | 上海市第十人民医院 | Stem cell culture medium and application thereof and stem cell cultivation method |
| CN103555665A (en) * | 2013-08-12 | 2014-02-05 | 北京东方华辉生物医药科技有限公司 | SFM (serum-free medium) for culturing MSCs (mesenchymal stem cells) |
Non-Patent Citations (4)
| Title |
|---|
| G.S. TJABRINGA等: "The polymine spermine regulates osteogenic differentiation in adipose stem cells", 《J. CELL. MOL. MED》 * |
| 杨抚华，胡以平主编: "无血清培养基", 《医学细胞生物学》 * |
| 赵霞等: "不同培养基培养人脐血间充质干细胞的差异", 《中国组织工程研究》 * |
| 郑志竑，林玲编著: "天然培养基", 《神经细胞培养：理论与实践》 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107267444A (en) * | 2017-08-24 | 2017-10-20 | 广州润虹医药科技股份有限公司 | The method that culture medium and application thereof is converted with mescenchymal stem cell to sweat gland like cell |
| CN107267444B (en) * | 2017-08-24 | 2020-06-12 | 广州润虹医药科技股份有限公司 | Culture medium and application thereof, and method for transforming mesenchymal stem cells into sweat gland-like cells |
| CN109136170B (en) * | 2018-08-20 | 2022-02-18 | 东北农业大学 | Serum-free medium suitable for carp triploid cell growth and application thereof |
| CN109136170A (en) * | 2018-08-20 | 2019-01-04 | 东北农业大学 | A kind of serum free medium and its application suitable for carp three times somatic growth |
| CN109022356A (en) * | 2018-08-30 | 2018-12-18 | 丰泽康生物医药（深圳）有限公司 | A kind of serum free medium improving mesenchymal stem cells into chondrocytes differentiation |
| CN109136178A (en) * | 2018-08-30 | 2019-01-04 | 丰泽康生物医药（深圳）有限公司 | A kind of raising serum free medium of the peripheral blood multipotential cell to Chondrocyte Differentiation |
| CN109652364A (en) * | 2018-12-29 | 2019-04-19 | 广州和能生物科技有限公司 | A kind of serum free medium of human amnion membrane |
| CN109943525A (en) * | 2019-03-15 | 2019-06-28 | 广州医科大学附属第三医院 | Serum-free, non-animal derived ingredient, the specific culture medium of component and its application |
| CN111040945A (en) * | 2019-12-30 | 2020-04-21 | 安徽惠恩生物科技股份有限公司 | Multi-type stem cell culture dish and culture medium thereof |
| CN113512525A (en) * | 2020-04-10 | 2021-10-19 | 南京大学 | Mesenchymal stem cell preparation and application thereof |
| CN111808807B (en) * | 2020-07-21 | 2021-07-30 | 生物岛实验室 | Mesenchymal stem cell serum-free medium without need of pre-coating and application thereof |
| CN111808807A (en) * | 2020-07-21 | 2020-10-23 | 生物岛实验室 | Mesenchymal stem cell serum-free medium without need of pre-coating and application thereof |
| CN112029717A (en) * | 2020-09-17 | 2020-12-04 | 英科博雅基因科技（天津）有限公司 | Serum-free in vitro domestication culture of human mesenchymal stem cells |
| CN112029717B (en) * | 2020-09-17 | 2023-11-03 | 深圳博雅感知药业有限公司 | Serum-free in vitro domestication culture of human mesenchymal stem cells |
| CN113388574A (en) * | 2021-05-12 | 2021-09-14 | 生物岛实验室 | Serum-free and feed layer-free culture medium and culture method for effectively inhibiting stem cell differentiation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104877963A (en) | Serum-free human umbilical cord mesenchymal stem cell culture medium and preparation method thereof | |
| CN104877961A (en) | Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof | |
| CN104877962A (en) | Serum-free adipose-derived stem cell culture medium and preparation method thereof | |
| CN103805562B (en) | Cultivate the serum free medium of placenta mesenchyma stem cell | |
| CN110923196B (en) | Serum-free medium, preparation method thereof and mesenchymal stem cell culture method | |
| CN112322580B (en) | Application of serum-free medium for mesenchymal stem cells | |
| CN105112365A (en) | Serum-free medium for human umbilical cord mesenchymal stem cells and preparation method thereof | |
| CN106635978B (en) | A kind of umbilical cord mesenchymal stem cells serum free medium and its preparation method and application | |
| CN105112364A (en) | Serum-free medium for human adipose-derived stem cells and preparation method thereof | |
| CN104805054B (en) | Stem cell serum-free culture medium | |
| CN109762782B (en) | Culture medium for promoting growth of mesenchymal stem cells and preparation method thereof | |
| Quattrocelli et al. | Mouse and human mesoangioblasts: isolation and characterization from adult skeletal muscles | |
| CN106754675B (en) | A kind of fat stem cell serum free medium and its preparation method and application | |
| CN105420182A (en) | Serum-free medium for umbilical cord mesenchymal stem cells | |
| CN101748096A (en) | Sub totipotential stem cell and preparation method and application thereof | |
| CN109749997B (en) | Limbal stem cell serum-free medium and culture method thereof | |
| CN105112362A (en) | Serum-free medium for placenta-derived mesenchymal stem cells and preparation method thereof | |
| CN109943526B (en) | A kind of serum-free peptide composition promoting mescenchymal stem cell proliferation | |
| CN107574145A (en) | serum free medium | |
| CN104830753B (en) | A kind of induced multi-potent stem cell culture medium, application and cultural method | |
| CN113736729B (en) | Composition, serum-free medium containing composition and stem cell culture method | |
| CN105112363A (en) | Serum-free medium for human adipose-derived stem cells and preparation method thereof | |
| CN103087977A (en) | Culture solution for in vitro efficient amplification of animal cells and application of culture solution | |
| CN110257328A (en) | A kind of mesenchymal stem cell serum-free culture medium | |
| CN114480273A (en) | Culture medium for obtaining mesenchymal stem cells and exosomes thereof and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150902 |
|
| RJ01 | Rejection of invention patent application after publication |